News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Apr 15, 2026 at 14:11 Big Tech Rising Hot

What’s the deal with Alzheimer’s disease and amyloid?

For decades, scientists have concentrated on what now looks to be a blind alley.

Signal weather

Rising

Momentum is building quickly, so this card is a good early entry point into the topic.

By Jonathan M. Gitlin Original source
What’s the deal with Alzheimer’s disease and amyloid?

At the end of last month, a scientific journal pulled a research paper on Alzheimer's disease. The retraction came from Neurobiology of Aging, which removed a 2011 paper claiming to show that a version of a protein called amyloid-β was responsible for memory loss in Alzheimer's disease. On its own, that might not seem notable; bad papers can make it through peer review and are only caught after publication. But this wasn't an isolated case. Over the past few years, multiple studies arguing that amyloid-β is the central driver of Alzheimer's disease have been retracted. Some scientists have even been indicted for fraud over the issue. All the while, none of the drugs targeting this protein and its pathway have had any real clinical effect. Read full article Comments

Stay on the signal

Follow What’s the deal with Alzheimer’s disease and amyloid?

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

Fresh coverage with immediate momentum.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Alzheimer, Amyloid, and Ars Technica, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Apr 16, 2026 at 23:20 Ars Technica

Lucasfilm drops The Mandalorian and Grogu final trailer at CinemaCon

"The old protect the young, and then the young protect the old."

Apr 16, 2026 at 21:33 Ars Technica

Intel refreshes non-Ultra Core CPUs with new silicon for the first time

For the first time in a while, the benefits of new Intel tech will trickle down.

Apr 16, 2026 at 21:17 Ars Technica

OpenAI starts offering a biology-tuned LLM

GPT-Rosalind is an LLM trained on biology workflows, available in closed access.

Apr 16, 2026 at 21:00 Ars Technica

As they got close to the Moon, Artemis II astronauts were eager to land

"If you had given us the keys to the lander, we would have taken it down."

Apr 16, 2026 at 20:43 Ars Technica

Mozilla launches Thunderbolt AI client with focus on self-hosted infrastructure

New tool builds on deepset’s Haystack toward a “decentralized open source AI ecosystem.”

Apr 15, 2026 at 14:11 Ars Technica

What’s the deal with Alzheimer’s disease and amyloid?

For decades, scientists have concentrated on what now looks to be a blind alley.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page